Significance of L-carnitine in internal medicine

被引：7

作者：

Sizova, Zh M. ^{[1
]}

Shikh, E., V ^{[1
]}

Makhova, A. A. ^{[1
]}

机构：

[1] IM Sechenov First Moscow State Med Univ, Sechenov Univ, Minist Hlth Russian Federat, Moscow, Russia

来源：

TERAPEVTICHESKII ARKHIV | 2019年 / 91卷 / 01期

关键词：

L-carnitine; P450; CYP; 3A4; chronic heart failure; myocardial infarction; chronic renal failure; inter-drug interaction; antioxidant; antihypoxant; ACETYL-L-CARNITINE; STAGE RENAL-DISEASE; MYOCARDIAL-INFARCTION; HEMODIALYSIS-PATIENTS; EXERCISE TOLERANCE; STABLE ANGINA; OLD RATS; SUPPLEMENTATION; DEFICIENCY; THERAPY;

D O I：

10.26442/00403660.2019.01.000040

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The review presents the results of a number of experimental and clinical studies proving the prospects of using L-carnitine in the clinic of internal diseases. Due to the antioxidant and antihypoxant properties, the additional use of L-carnitine in addition to the main etiopathogenetic therapy is prescribed by cardiologists, nephrologists, neurologists, gerontologists. Experimental studies we conducted earlier showed no effect of L-carnitine on the activity of the P450 CYP 3A4 system, which reduces the likelihood of drug-drug interaction at the level of metabolism of drugs metabolized by P450 3A4. When using L-carnitine as part of complex pharmacotherapy, the drug has an increased safety profile in comorbid patients taking L-carnitine.

引用

页码：114 / 120

页数：7

共 53 条

[11] Chichanovskaya LV, 2017, J NEUROL PSYCHIAT, V2, P65
[12] Myocardial infarction and left ventricular remodeling: Results of the CEDIM trial
Colonna, P
Iliceto, S
[J]. AMERICAN HEART JOURNAL, 2000, 139 (02) : S124 - S130
[13] AGE-DEPENDENT DECREASE OF CARNITINE CONTENT IN MUSCLE OF MICE AND HUMANS
COSTELL, M
OCONNOR, JE
GRISOLIA, S
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 161 (03) : 1135 - 1143
[14] DAVINI P, 1992, DRUG EXP CLIN RES, V18, P355
[15] Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy: A long-term, randomised, double-blind, placebo-controlled study
De Grandis D.
Minardi C.
[J]. Drugs in R & D, 2002, 3 (4) : 223 - 231
[16] L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis
DiNicolantonio, James J.
Lavie, Carl J.
Fares, Hassan
Menezes, Arthur R.
O'Keefe, James H.
[J]. MAYO CLINIC PROCEEDINGS, 2013, 88 (06) : 544 - 551
[17] Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder - National Kidney Foundation - Carnitine consensus conference
Eknoyan, G
Latos, DL
Lindberg, J
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) : 868 - 876
[18] The role of the carnitine system in human metabolism
Foster, DW
[J]. CARNITINE: THE SCIENCE BEHIND A CONDITIONALLY ESSENTIAL NUTRIENT, 2004, 1033 : 1 - 16
[19] Gleser MG, 2015, CARDIOLOGY, V55, P4
[20] Glezer M.G., 2015, HEART J, V14, P78

← 1 2 3 4 5 6 →